Annexon, Inc. (ANNX)
| Market Cap | 682.48M +107.0% |
| Revenue (ttm) | n/a |
| Net Income | -202.67M |
| EPS | -1.13 |
| Shares Out | 189.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,653,845 |
| Open | 3.700 |
| Previous Close | 3.670 |
| Day's Range | 3.500 - 3.820 |
| 52-Week Range | 2.540 - 7.180 |
| Beta | 1.33 |
| Analysts | Buy |
| Price Target | 15.43 (+328.61%) |
| Est. Earnings | Nov 9, 2026 |
About ANNX
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ANNX stock is "Buy." The 12-month stock price target is $15.43, which is an increase of 328.61% from the latest price.
News
Annexon price target raised to $15 from $14 at JPMorgan
JPMorgan raised the firm’s price target on Annexon (ANNX) to $15 from $14 and keeps an Overweight rating on the shares. Topline 15-month data from the Phase 3 ARCHER II…
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision Outcomes ARCHER II is the First Pivotal Tri...
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflamma...
Annexon Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The conference highlighted late-stage programs in geographic atrophy and Guillain-Barré syndrome, with phase III data showing strong vision preservation and rapid patient recovery, respectively. The GA program’s dual primary endpoints and robust design position it for global regulatory filings and significant market impact.
Annexon Transcript: Wells Fargo 21st Annual Healthcare Conference
Late-stage programs in GBS and GA are advancing, with strong clinical data and regulatory filings in progress. The GA study's unique focus on functional vision and mechanistic differentiation positions it for significant market impact, while the GBS program shows rapid, meaningful patient benefit and a targeted commercial approach.
Annexon to Participate in Upcoming September Investor Conferences
BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflamma...
Annexon price target raised to $14 from $10 at JPMorgan
JPMorgan raised the firm’s price target on Annexon (ANNX) to $14 from $10 and keeps an Overweight rating on the shares after having hosted a call focused on tanruprubart in…
Annexon participates in a conference call with JPMorgan
Conference call with management will be held on August 17 at 12 pm hosted by JPMorgan.Webcast Link
Annexon reports Q2 EPS (28c), consensus (24c)
Cash, cash equivalents and short-term investments were $209.2M as of June 30, 2026. Annexon’s (ANNX) current cash, cash equivalents and short-term investments and funds from the credit facility are ex...
Annexon expands Phase 3 ARCHER II trial
Annexon (ANNX) announced the addition of a Month 24 dual primary endpoint to complement the current Month 15 primary endpoint in its Phase 3 ARCHER II trial, and launch of…
Annexon upgraded to Market Perform from Underperform at Citizens
Citizens analyst Jonathan Wolleben upgraded Annexon (ANNX) to Market Perform from Underperform without a price target The firm says adding vision preservation at month 24 as an independent, dual prima...
Annexon Earnings Call Transcript: Q2 2026
Expanded phase III trial for GA with a new 24-month endpoint and reported rapid, positive results for GBS therapy. Financial position strengthened with a $200M credit facility, and key regulatory filings are on track for both programs.
Annexon Earnings release: Q2 2026
Annexon released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Annexon Quarterly report: Q2 2026
Annexon has published its Q2 2026 quarterly earnings report on August 12, 2026.
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submissio...
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinfla...
Annexon announces tanruprubart data from FORWARD study
Annexon (ANNX) announced early improvement in strength and clinically meaningful reduction in disability shown with tanruprubart in the first ten U.S. and European patients with Guillain-Barre syndrom...
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
Expands Financial Capacity as Vonaprument and Tanruprubart Programs Advance Toward Registration Expands Financial Capacity as Vonaprument and Tanruprubart Programs Advance Toward Registration
Annexon initiated with an Underperform at Citizens
Citizens initiated coverage of Annexon (ANNX) with an Underperform rating and $3 price target The company is developing first-in-class C1q inhibitors targeting the initiating step of the classical com...
Annexon price target raised to $25 from $11 at Needham
Needham analyst Joseph Stringer raised the firm’s price target on Annexon (ANNX) to $25 from $11 and keeps a Buy rating on the shares. The company plans to announce topline…
Annexon to present vonaprument data at ASRS
Annexon (ANNX) announced an oral presentation on the neuroprotective effect of vonaprument at the American Society of Retina Specialists, or ASRS, 44th Annual Scientific Meeting being held July 15-18 ...
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
BRISBANE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammat...
Nedham biotech analysts hold an analyst/industry conference call
Analysts discuss Annexon (ANNX) Vonaprument in geographic atrophy on an Analyst/Industry conference call on July 9 at 9 am.
Annexon Transcript: AGM 2026
The meeting covered progress on late-stage therapies for neuroinflammatory diseases, approved all four shareholder proposals, and confirmed a strong cash position through 2027. Key milestones include regulatory submissions and pivotal data readouts.